# **Key Information Document**



## Purpose

This document provides you with key information about this investment Product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this Product and to help you compare it with other products.

Product			
Product Name:	Lumyna - MW TOPS UCITS Fund - USD J (dis), a sub-fund of Lumyna - Marshall Wace UCITS SICAV (the "Product")		
Product Identifier:	ISIN: LU2367651135		
Product Manufacturer:	Generali Investments Luxembourg S.A. ("We"), part of Assicurazioni Generali Group		
Contact Details: Website: www.lumyna.com Call: +44 (0) 20 3997 0100 for more information			
Competent Regulatory Authority:	This Product is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier.		
	Generali Investments Luxembourg S.A., as management company is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier.		

This document is accurate as of 30 August 2024.

## What is this Product?

#### **Objectives**:

The investment objective of the Product is to provide investors with consistent positive performance primarily through investing in the equities of companies incorporated or active in Europe. The Product may also invest in debt securities, which may be government or corporate.

The Product invests systematically on the basis of investment ideas and scoring from third-party contributors, selected and refined by Marshall Wace LLP's Trade Optimised Portfolio System ("TOPS") investment process. The Investment Manager can also add its own investment ideas to the Product's portfolio.

The portfolio construction process involves five key elements: investment idea collection to capture and analyse the investment ideas, contributor relationship management to ensure contributors regularly appraise their ideas, optimisation which aims to implement the ideas in a diversified way and in accordance with risk/reward targets, risk management and trade execution as further described in the prospectus.

The Product may use derivatives, including over-the-counter swap transactions, options, warrants, futures and forward contracts to achieve the investment objective.

The Product will primarily focus in Europe but will not focus on any specific sector. Leverage will only be achieved through derivatives.

The return of the Product is also related to the recommended holding period and risk and reward profile.

For further information, please see the "Investment Objective" and "Investment Policy" sections of the Product's supplement to the prospectus.

Unless otherwise defined in this document, all words and expressions defined in the Product's current prospectus shall have the same meaning herein.

## Term:

The Product has no maturity date.

## Benchmark:

The Product is actively managed, and is not managed in reference to a benchmark.

#### Type:

This Product is a Share class of Lumyna - MW TOPS UCITS Fund (the "Sub-Fund"), a sub-fund of Lumyna - Marshall Wace UCITS SICAV (the "Fund"), a UCITS fund organised as a public limited company and qualifying as an investment company with variable capital with multiple sub-funds.

The performance of this Product will depend on the performance of the portfolio of investments of the Sub-Fund, as further described in the section "Objectives" of this document.

## Intended Retail Investor:

This Product is suitable for:

- Investors seeking growth through an actively managed fund invested across different types of assets.

Investors with a knowledge level of a basic, informed and advanced investor.
Retail investors who rely on investment advice and portfolio management

services.

- Investors who have an investment horizon of 5 years or more.

- Investors who are able to bear the loss of their entire investments due to market risks as described in the section "What are the risks and what could I get in return?" below.

#### Depositary:

J.P. Morgan SE, Luxembourg Branch ("the Depositary").

### **Distribution Policy:**

This Product may pay dividends.

## Dealing:

Investors can redeem and subscribe for Shares in the Product on demand on any Wednesday on which banks are open for business in Luxembourg, London and Dublin or the next following Business Day if such day is not a Business Day.


The assets and liabilities of the Sub-Fund are segregated from the other sub-funds of the Fund by law. However, the assets and liabilities of your Shares are not segregated from the assets and liabilities of the other classes of Shares of the Sub-Fund.

You are able to convert your Shares into other classes of Shares in sub-funds of the Fund. Further information about how to do this can be found in the Fund's prospectus.

The Product's latest prospectus, annual and semi-annual reports, updated KIDs, other product information, including the prices of the Shares are available, free of charge, in English at www.lumyna.com. Such prospectus and reports are prepared at the level of the Fund as a whole.

## What are the risks and what could I get in return?

#### **Risk Indicator**



The summary risk indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets or because we are not able to pay you.

Performance Scenarios

The figures shown include all the costs of the Product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. What you will get from this Product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

We have classified this Product as 3 out of 7, which is a medium-low risk class. This rates the potential losses from future performance at a medium-low level, and poor market conditions are unlikely to impact our capacity to pay you.

Be aware of currency risk if your reference currency differs from the currency of the Product. You may receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

Please refer to the Product's prospectus for a full list of risks which can affect the overall Product value.

This Product does not include any protection from future market performance so you could lose some or all of your investment. If we are not able to pay you what is owed, you could lose your entire investment.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average and best performance of the Product and/or its benchmark over the last 10 years. Markets could develop very differently in the future. The stress scenario shows what you might get back in extreme market circumstances.

Recommended Holding Period5 yearsExample InvestmentUSD 10,000		5 years			
Scenarios			If you exit after 1 year	If you exit after 5 years (Recommended Holding Period)	
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.				
Stress	What you might get bacl	after costs	USD 7.416	USD 7.475	
	Average return each year		-25,8%	-5,7%	
Unfavourable	What you might get bacl	after costs	USD 10.136	USD 10.696	
	Average return each year		1,4%	1,4%	
	This scenario occurred f 03/2020.	or an investment between 04/2015 and			
Moderate	What you might get bacl	after costs	USD 10.548	USD 13.059	
	Average return each year		5,5%	5,5%	
	This scenario occurred f 07/2019.	or an investment between 08/2014 and			
Favourable	What you might get bacl	after costs	USD 10.849	USD 15.027	
	Average return each year		8,5 %	8,5%	
	This scenario occurred f 07/2024.	or an investment between 08/2019 and			

## What happens if Generali Investments Luxembourg S.A. is unable to pay out?

You are not covered by any investor compensation or guarantee scheme. To protect you, your assets are held with a separate company, the Depositary. While you will not face a financial loss should we default, in the event of the Depositary's default you may suffer a financial loss. This risk is mitigated as the Depositary is required to segregate its own assets from the assets of the Fund. However, the risk does still exist and you could lose your entire investment.

#### What are the costs?

The person advising on or selling this Product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

#### Table 1: Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the Product and how well the Product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods. We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the Product performs as shown in the moderate scenario.
- USD 10,000 is invested.

	If you exit after 1 year	If you exit after 5 years
Total Costs	USD 650	USD 3.643
Annual Cost Impact (*)	6,5%	6,7% each year

\* This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 12,2% before costs and 5,5% after costs.

# What are the costs? (continued)

#### **Table 2: Composition of costs**

One-off costs upon entry or exit	Impact on return if you exit after one year				
Entry costs	We do not charge an entry fee for this Product.	USD 0			
Exit costs	We do not charge an exit fee for this Product.	USD 0			
Ongoing costs taken each year					
Management fees and other administrative or operating costs	2,75% of the value of your investment per year. This is an estimate based on actual costs over the last year.	USD 275			
Transaction costs	2,02% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the Product. The actual amount will vary depending on how much we buy and sell.	USD 202			
Incidental costs taken under specific conditions					
Performance fees (and carried interest)	We take performance fees from your investment of 20% of the outperformance against the High Water Mark. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years.	USD 173			

A conversion charge of up to 5% of the value of the Shares to be converted may apply. This charge only applies if you convert the Shares you hold into other classes of Shares in a Sub-Fund of the Fund.

## How long should I hold it and can I take money out early?

## **Recommended holding period: 5 years**

The Product has no required minimum holding period but is designed for long term investments; you should be prepared to stay invested for at least 5 years. However, you can redeem your investment without penalty at any time during this period, or hold the investment longer. The impact of cashing in early could result in a lower return.

## How can I complain?

You can send your complaints to the Product's Management Company at Generali Investments Luxembourg S.A. Attention: Complaints Handling Officer 4, rue Jean Monnet L-2180 Luxembourg or by e-mail to gil\_complaint@generali-invest.com. Details of the Management Company's complaints handing policy may be found on www.lumyna.com.

If you have a complaint about the person that advised you about this Product, or who sold it to you, they will tell you where to complain.

## Other relevant information

The Product's past performance for up to the last 10 years and the previously published performance scenario information is available on our website at www.lumyna.com.

The Product's paying agent and representative in Switzerland is Société Générale, Talacker 50, P.O. Box 5070, CH-8021 Zurich. The prospectus, the Key Information Documents, the articles of incorporation as well as the annual and semi-annual reports of the Fund may be obtained free of charge from the Product's representative.